Natera slides nearly 5% as profit-taking hits after MRD royalty win
Natera shares fell about 5% to around $194 as traders faded a sharp run-up and digested mixed signals after a key MRD patent ruling. The drop also followed recent analyst target trims and elevated investor focus on valuation and insider selling.
1. What’s happening in NTRA today
Natera (NTRA) is trading down roughly 4.9% to about $194, extending a pullback after the stock failed to hold recent highs near the low-$200s. The move is occurring amid heavy debate over how much of the recent optimism was already priced in and whether near-term valuation can be justified as the company scales Signatera and other testing volumes.
2. Key catalyst: post-ruling giveback and positioning reset
The stock’s decline comes right after a notable legal win in Natera’s MRD patent fight, in which a judge awarded Natera an ongoing 30% royalty—news that helped drive a sharp premarket pop on April 9. The next session’s drop looks like a classic “sell the news” reaction: investors locked in gains after the surge and rebalanced exposure as the market reassessed timing, collectability, and ultimate financial impact of the ruling.
3. Analyst/valuation cross-currents add pressure
Separately, recent research activity has included modest price-target trims (while keeping bullish ratings) and broader investor scrutiny of valuation. That combination can amplify downside on red-market tape days: when expectations are high, even positive developments can be met with profit-taking rather than fresh buying.
4. What to watch next
Investors are now focused on whether Natera can stabilize above key technical support around the high-$180s to low-$190s area and whether follow-through details emerge on the royalty framework and any potential appeals. The next scheduled company financial update is expected May 7, 2026, which could reset sentiment depending on revenue growth, margin trajectory, and outlook commentary.